Podcast Episodes
Back to Search
Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity
Co-Founder & CSO Martin Borch Jensen describes the deal and walks us through Gordian's process that enables it to do a multiplicity of in vivo screen…
6 months, 4 weeks ago
Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate
CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial s…
6 months, 4 weeks ago
Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD
The study showed that AXPAXLI has superior maintenance of visual acuity at Week 36 vs EYLEA. Dr. Dugel discusses what he believes the significance of…
6 months, 4 weeks ago
Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year
Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the…
6 months, 4 weeks ago
From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia
He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typic…
6 months, 4 weeks ago
From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases
He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the…
6 months, 4 weeks ago
Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more
MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Will…
7 months ago
Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened
He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take o…
7 months ago
Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic r…
7 months ago
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.
7 months, 2 weeks ago